Bai Jianling

发布者:公共卫生学院发布时间:2022-10-25浏览次数:520

Vice Director of  Department of  Biostatistics, School of  Public Health, Nanjing Medical University

Associate Professor of  Biostatistics

Member of Committee of Statistical Experts, Chinese Society of Clinical Oncology

Member of Committee of Statistical Education, Chinese Medical Informationand Health Big Data Society

baijianling@njmu.edu.cn

柏建岭, 博士副教授

Jianling Bai, MD, PhD




Research Interest

Statistical methods and applications in medical research

Clinical research design and analysis

Data mining

Data visualization


Education

Nantong  Medical  College, Preventive  Medicine, B.S. (1996.9-2001.7)

Nanjing  Medical  University, Epidemiology  and  Biostatistics, Ph.D.(2004.9-2009.7)

Indiana  University  Bloomington, USA,  Epidemiology  and  Biostatistics,  Visiting  scholar (2013.9-2014.9)


Honors and Awards:

2017   Young  teachers'  Scholarship  of   Nanjing  Medical  University

2020   Advanced individual in Three-Full Education   of  Nanjing  Medical  University


Research Projects

  • PI, Detection of gene-gene/environment interaction  in  genome research. The Natural  Science  Foundation  of  the  Jiangsu  Higher  Education  Institutions  if  China, 10KJB330002

  • PI, Design  and statistical  methods  of  multiregional  clinical  trial. NSFC,81302512


Selected Papers

  1. LuX, Lv C, Zhao Y, Wang Y, Li Y, Ji C, Wang Z, Ye W, Yu S, BaiJ, Cai W. TSG-6 released from adipose stem cells-derived small extracellular vesicle protects against spinal cord ischemia reperfusion injury by inhibiting endoplasmic reticulum stress. Stem Cell Res Ther. 2022,13(1):291.

  2. GengR, Song J, Zhong Z, Ni S, Liu W, He Z, Gan S, Huang Q, Yu H, BaiJ, Liu J. Cross talk of Redox-Related Subtypes, Establishment of a Prognostic Model and Immune Responses in Endometrial Carcinoma. Cancers (Basel).2022,14(14):3383.

  3. NiS, Yu Q, Zhong Z, Yang M, Zhao Y, Wu J, BaiJ, Yu H. Risk difference, relative risk, and odds ratio for non-inferiority clinical trials with risk rate endpoint. J Biopharm Stat. 2022,1-16.

  4. LiuW, Zhao Y, Wang G, Feng S, Ge X, Ye W, Wang Z, Zhu Y, Cai W, BaiJ, Zhou X. TRIM22 inhibits osteosarcoma progression through destabilizing NRF2 and thus activation of ROS/AMPK/mTOR/autophagy signaling. Redox Biol.2022,53:102344.

  5. LiuJ, Geng R, Ni S, Cai L, Yang S, Shao F, BaiJ. Pyroptosis-related lncRNAs are potential biomarkers for predicting prognoses and immune responses in patients with UCEC. Mol Ther Nucleic Acids. Mol Ther Nucleic Acids. 2022,27:1036-1055.

  6. NiS, Zhong Z, Wei J, Zhou J, Cai L, Yang M, Xun P, Zhao Y, Yu H,Bai J. Association between dietary intake of poly unsaturated fatty acid and prevalence of hypertension in U.S. adults: A cross-sectional study using data from NHANES 2009-2016. Hypertens Res. 2022,45(3):516-526.

  7. ChenY, Liu C, Wang T, Qi J, Jia X, Zeng X, BaiJ, Lu W, Deng Y,Zhong B, He W, Xing Y, Lian Z, Zhou H, Yan J, Yang X, Yu H, Zhou J,Zhou D, Qiu L, Zhong N, Wang J. Efficacy and safety of Bufei Huoxuecapsules in the management of convalescent patients with COVID-19infection: A multicentre, double-blind, and randomised controlledtrial. J Ethnopharmacol. 2022,284:114830.

  8. WuY, Bai J,Zhang M, Shao F, Yi H, You D, Zhao Y. Heterogeneity of TreatmentEffects for Intensive Blood Pressure Therapy by Individual Components of FRS: An Unsupervised Data-Driven Subgroup Analysis inSPRINT and ACCORD. Front Cardiovasc Med. 2022,9:778756.

  9. FuZ, Wu Q, Guo W, Gu J, Zheng X, Gong Y, Lu C, Ye J, Ye X, Jiang W, HuM, Yu B, Fu Q, Liu X, BaiJ, Li JZ, Yang T,Zhou H. Impaired Insulin Clearance as the Initial Regulator ofObesity-Associated Hyperinsulinemia: Novel Insight Into theUnderlying Mechanism Based on Serum Bile Acid Profiles. Diabetes Care. 2022,45(2):425-435.

  10. LiuJ, Wang Y, Yin J, Yang Y, Geng R, Zhong Z, Ni S, Liu W, Du M, Yu H,Bai J.Pan-Cancer Analysis Revealed SRSF9 as a New Biomarker for Prognosisand Immunotherapy. J Oncol. 2022,2022:3477148.

  11. ZhangJ, Pan Y, Shi Q, Zhang G, Jiang L, Dong X, Gu K, Wang H, Zhang X,Yang N, Li Y, Xiong J, Yi T, Peng M, Song Y, Fan Y, Cui J, Chen G,Tan W, Zang A, Guo Q, Zhao G, Wang Z, He J, Yao W, Wu X, Chen K, HuX, Hu C, Yue L, Jiang D, Wang G, Liu J, Yu G, Li J, BaiJ, Xie W, Zhao W, WuL, Zhou C. Paclitaxel liposome for injection (Lipusu) plus cisplatinversus gemcitabine plus cisplatin in the first-line treatment oflocally advanced or metastatic lung squamous cell carcinoma: Amulticenter, randomized, open-label, parallel controlled clinicalstudy. Cancer Commun (Lond). 2022,42(1):3-16.

  12. ZhouJ, Cai L, Ni S, Zhong Z, Yang M, Yu H, Zhao Y, Xun P,Bai J. Associations of dietary PUFA with dyslipidaemia among the US adults: the findings from National Health and Nutrition Examination Survey (NHANES)2009-2016. Br J Nutr. 2022,7:1386-1394.

  13. LiuJ, Geng R, Yang S, Shao F, Zhong Z, Yang M, Ni S, Cai L, BaiJ. Development and Clinical Validation of  Novel 8-Gene Prognostic Signature Associated With the Proportion of Regulatory T Cells by Weighted Gene Co-Expression Network Analysis in Uterine Corpus Endometrial Carcinoma. Front Immunol. 2021,12:788431.

  14. LiuW, Tang P, Wang J, Ye W, Ge X, Rong Y, Ji C, Wang Z, BaiJ, Fan J, Yin G, CaiW. Extracellular vesicles derived from melatonin-preconditioned mesenchymal stem cells containing USP29 repair traumatic spinal cordinjury by stabilizing NRF2. J Pineal Res. 2021,71(4):e12769.

  15. LiuJ, Chen T, Yang M, Zhong Z, Ni S, Yang S, Shao F, Cai L, BaiJ, Yu H. Development of an Oxidative Phosphorylation-Related and Immune Microenvironment Prognostic Signature in Uterine Corpus Endometrial Carcinoma. Front Cell Dev Biol. 2021,9:753004.

  16. LiuJ, Chen C, Wang Y, Qian C, Wei J, Xing Y,Bai J. Comprehensive of  N1-Methyladenosine Modifications Patterns and Immunological Characteristics in Ovarian Cancer. Front  Immunol. 2021,12:746647.

  17. LiuJ, Wang Y, Yuan S, Wei J, BaiJ. Construction of an Immune Cell Infiltration Score to Evaluate the Prognosis and Therapeutic Efficacy of Ovarian Cancer Patients. Front Immunol.2021,12:751594.

  18. QianC, Liang Y, Yang M, Bao SN, BaiJL, Yin YM, Yu H.Effect of breast- conserving surgery plus radiotherapy versus mastectomy on breast cancer-specific survival for early-stage contralateral breast cancer. Gland Surg. 2021,10(10):2978-2996.

  19. ChenY, He W, Lu W, Xing Y, BaiJ, Yu H, Zhou J,Liang J, Chen J, Hou C, Zhong B, Wang T, Feng H, Chen X, Wang T,Yang K, Zhang N, Zhong N, Liu C, Wang J. Bufei huoxue capsules inthe management of convalescent COVID-19 infection: study protocol for a multicenter, double-blind, and randomized controlled trial.Pulm Circ. 2021,11(3):20458940211032125.

  20. GeX, Liu W, Zhao W, Feng S, Duan A, Ji C, Shen K, Liu W, Zhou J, JiangD, Rong Y, Gong F, Wang J, Xu Z, Li X, Fan J, Wei Y, BaiJ, Cai W. ExosomalTransfer of LCP1 Promotes Osteosarcoma Cell Tumorigenesis and Metastasis by Activating the JAK2/STAT3 Signaling Pathway. Mol TherNucleic Acids. 2020,21:900-915.

  21. QinF, Wu J, Chen F, Wei Y, Zhao Y, Jiang Z, BaiJ, Yu H. Optimal,minimax and admissible two-stage design for phase II oncologyclinical trials. BMC Med Res Methodol. 2020,20(1):126.